PubRank

K Doney

Author PubWeight™ 84.75‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986 3.22
2 Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989 2.61
3 Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989 2.42
4 A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990 2.32
5 Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 1996 2.30
6 Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992 2.14
7 Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990 2.09
8 Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 1983 1.89
9 Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol 1988 1.72
10 Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. Br J Haematol 1989 1.57
11 Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994 1.57
12 Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiation. Br J Haematol 1996 1.47
13 Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986 1.41
14 Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001 1.41
15 Does graft-versus-host disease influence the tempo of immunologic recovery after allogeneic human marrow transplantation? An observation on 56 long-term survivors. Blood 1978 1.33
16 Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986 1.30
17 Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anaemia. Br J Haematol 1983 1.23
18 Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant 2001 1.13
19 Decreased incidence of marrow graft rejection in patients with severe aplastic anemia: changing impact of risk factors. Blood 1986 1.07
20 Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. Blood 1986 1.07
21 Effect of peripheral blood lymphocytes from patients with aplastic anemia on granulocytic colony growth from HLA-matched and -mismatched marrows: effect of transfusion sensitization. Blood 1978 1.07
22 Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993 1.05
23 Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. Blood 1995 1.05
24 Results of phase III excimer laser photorefractive keratectomy for myopia. The Summit PRK Study Group. Ophthalmology 1997 1.05
25 Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia. Exp Hematol 1987 1.03
26 Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation. Lancet 1982 1.03
27 Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine. Am J Med 1985 1.00
28 Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood 1997 0.99
29 Antihuman thymocyte globulin for prophylaxis of graft-versus-host disease. A randomized trial in patients with leukemia treated with HLA-identical sibling marrow grafts. Transplantation 1979 0.98
30 Marrow transplantation for aplastic anemia. Semin Hematol 1984 0.98
31 Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant 2009 0.97
32 Allogeneic marrow transplantation following cyclophosphamide and escalating doses of hyperfractionated total body irradiation in patients with advanced lymphoid malignancies: a Phase I/II trial. Int J Radiat Oncol Biol Phys 1995 0.93
33 Marrow transplantation for children with acute lymphoblastic leukemia in second remission. Blood 1987 0.92
34 Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia. Bone Marrow Transplant 1994 0.92
35 Changing trends in marrow transplantation for aplastic anemia. Bone Marrow Transplant 1992 0.91
36 Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. Ann Intern Med 1987 0.90
37 Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 1988 0.90
38 Increased prevalence of CMV gB3 in marrow of patients with aplastic anemia. Blood 2001 0.90
39 Treatment of aplastic anemia with antithymocyte globulin, high-dose corticosteroids, and androgens. Exp Hematol 1987 0.89
40 Recovery of in vivo cellular immunity after human marrow grafting. Influence of time postgrafting and acute graft-versus-host disease. Transplantation 1984 0.89
41 Growth and development in children after bone marrow transplantation. Horm Res 1988 0.89
42 Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood 1996 0.88
43 Immunosuppressive therapy for aplastic anemia: indications, agents, mechanisms, and results. Am J Pediatr Hematol Oncol 1990 0.87
44 Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. Transplantation 1990 0.87
45 Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994 0.87
46 Therapy of severe aplastic anemia with anti-human thymocyte globulin and androgens: the effect of HLA-haploidentical marrow infusion. Blood 1984 0.87
47 Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives. An update of the Seattle experience. Transplantation 1996 0.85
48 What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 1990 0.85
49 Antithoracic duct lymphocyte globulin therapy of severe aplastic anemia. Blood 1983 0.84
50 Marrow transplantation for treatment of pregnancy-associated aplastic anemia. Exp Hematol 1985 0.83
51 Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Bone Marrow Transplant 2000 0.83
52 Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine? Biol Blood Marrow Transplant 1997 0.82
53 Unrelated donor or autologous marrow transplantation for treatment of acute leukemia. Blood 1994 0.82
54 Genetically identical twin transplantation for chronic lymphocytic leukemia. Leukemia 2007 0.81
55 A randomized trial of antihuman thymocyte globulin versus murine monoclonal antihuman T-cell antibodies as immunosuppressive therapy for aplastic anemia. Exp Hematol 1985 0.81
56 Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. Bone Marrow Transplant 1986 0.81
57 A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. Br J Haematol 1992 0.81
58 Fanconi's anemia treated by allogeneic marrow transplantation. Blood 1983 0.80
59 Refractoriness to random donor platelet transfusions in patients with aplastic anaemia: a multivariate analysis of data from 264 cases. Br J Haematol 1987 0.80
60 Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. Transplantation 1985 0.80
61 Long term effects and quality of life in children and adults after marrow transplantation. Bone Marrow Transplant 1989 0.80
62 Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease. Transplant Proc 1987 0.80
63 Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody. Transplantation 1992 0.80
64 Treatment of chronic granulocytic leukemia by chemotherapy, total body irradiation and allogeneic bone marrow transplantation. Exp Hematol 1978 0.79
65 Marrow transplantation for leukemia following fractionated total body irradiation. A comparative trial of methotrexate and cyclosporine. Leuk Res 1985 0.79
66 Bone marrow transplantation experience for children with aplastic anemia. Pediatrics 1986 0.79
67 Marrow transplantation for severe aplastic anemia and thalassemia major. Semin Hematol 1991 0.79
68 Anti-human thymocyte globulin (ATG) for prophylaxis and treatment of graft-versus-host disease in recipients of allogeneic marrow grafts. Transplant Proc 1978 0.78
69 Graft-versus-host disease prophylaxis with methotrexate/cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts. Blood 1991 0.78
70 Cyclophosphamide plus ATG conditioning is insufficient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matched unrelated donors. Blood 1994 0.78
71 Marrow transplantation for hepatitis-associated aplastic anemia: a follow-up of long-term survivors. Biol Blood Marrow Transplant 1996 0.77
72 Marrow transplant experience for children with severe aplastic anemia. Am J Pediatr Hematol Oncol 1994 0.77
73 Donor buffy coat cell infusion after marrow transplantation for aplastic anemia. Blood 1988 0.77
74 Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Blood 1992 0.77
75 Late complications after marrow transplantation. Semin Hematol 1984 0.77
76 Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia. Blood 1994 0.76
77 Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3. Bone Marrow Transplant 1991 0.76
78 A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease. Transplantation 1990 0.76
79 Treatment of marrow graft recipients with thymopentin. Bone Marrow Transplant 1987 0.75
80 Does histologic grading of inflammation in bone marrow predict the response of aplastic anaemia patients to antithymocyte globulin therapy? Br J Haematol 1987 0.75
81 Growth and development after bone marrow transplantation. Prog Clin Biol Res 1989 0.75
82 Subsets of patients with aplastic anemia identified by flow microfluorometry. N Engl J Med 1985 0.75
83 HLA-identical marrow transplantation in the leukemias without T-cell depletion. The Seattle Marrow Transplant Team. Bone Marrow Transplant 1990 0.75
84 Long-term complications of bone marrow transplantation. Prog Clin Biol Res 1989 0.75
85 Correlation of two in vitro tests with clinical response to immunosuppressive therapy in 54 patients with severe aplastic anemia. Blood 1984 0.75
86 Marrow transplantation in hepatitis-associated aplastic anemia. Am J Hematol 1984 0.75
87 Second marrow transplants in patients with leukemia who relapse after allogeneic marrow transplantation. Bone Marrow Transplant 1988 0.75
88 Anti-thymocyte globulin therapy of hematologic disorders. Hawaii Med J 1987 0.75
89 Marrow transplantation for severe aplastic anemia: the Seattle experience. Prog Clin Biol Res 1984 0.75
90 Hematopoietic growth factors in human serum. erythroid burst-promoting activity in normal subjects and in patients with severe aplastic anemia. J Lab Clin Med 1985 0.75
91 Marrow transplantation for patients with acute lymphoblastic leukemia: the Seattle experience. Leukemia 1992 0.75
92 Marrow transplantation from HLA-identical siblings for treatment of aplastic anemia: is exposure to marrow donor blood products 24 hours before high-dose cyclophosphamide needed for successful engraftment? Blood 1983 0.75
93 Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. J Clin Oncol 1993 0.75
94 Recombinant interleukin-1 followed by immunosuppressive therapy for aplastic anemia. Am J Hematol 1996 0.75